Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Strengthens Compounding Safety with Cesium Ban And Research Collaboration

Executive Summary

FDA has taken additional steps to make drug compounding safer for patients, including a ban on cesium chloride because of “significant safety risks” it poses and a pair of university research collaborations to help further develop a list of bulk drug ingredients that can be safely compounded.

You may also be interested in...



Purported ‘Cancer Cure’ Linked To Heart Toxicity Is US FDA’s Latest Warning Target In Supplements

The ingredient, cesium chloride, also was the subject of a citizen petition by consumer advocacy group Public Citizen asking the FDA to prohibit its use in supplements. The FDA has warned five firms marketing products labeled as supplements and containing cesium chloride.

Public Citizen Strikes Out In Call For Opioid Approval Moratorium After Recent Win

Petition was consumer advocacy group's first request for halt to approval of an entire drug class; Public Citizen has gotten full and partial approval of other recent petitions.

Compounding Draft Guidance May End Par's Suit Against US FDA

Par says FDA shouldn't have authorized a compounded version of Vasostrict, but parties have asked court to wait until March, when a guidance is expected that may resolve the company's concerns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS123571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel